In this meta-analysis, we aimed to systematically evaluate the efficacy and safety of FDA-approved IDH inhibitors in the treatment of AML patients with IDH mutations by pooling and analyzing treatment response, survival, and safety-related data from relevant published prospective clinical studies. This evidence concerns the gene IDH2 and acute myeloid leukemia.